Influence of food and fluid ingestion on aspirin bioavailability. 1978

P A Koch, and C A Schultz, and R J Wills, and S L Hallquist, and P G Welling

The influence of test meals and accompanying fluid volume on aspirin bioavailability from commercial tablets was determined following single oral doses to healthy male volunteers. Plasma aspirin and salicylate levels were determined simultaneously using a GLC end-point. Area analysis indicated that approximately 5--8% of absorbed drug entered the systemic circulation as unchanged aspirin in nonfasted subjects compared to 16--18% in fasted individuals. Food tended to reduce the appearance rate of aspirin into the circulation, resulting in lower and somewhat more sustained levels than with fasting. Plasma salicylate levels were not influenced markedly by the various treatments, although levels were higher in fasted than in nonfasted subjects during the 1st hr after dosing. After this time, fat pretreatment tended to produce higher levels than other treatments.

UI MeSH Term Description Entries
D008297 Male Males
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D004326 Drinking The consumption of liquids. Water Consumption,Water Intake,Drinkings
D004435 Eating The consumption of edible substances. Dietary Intake,Feed Intake,Food Intake,Macronutrient Intake,Micronutrient Intake,Nutrient Intake,Nutritional Intake,Ingestion,Dietary Intakes,Feed Intakes,Intake, Dietary,Intake, Feed,Intake, Food,Intake, Macronutrient,Intake, Micronutrient,Intake, Nutrient,Intake, Nutritional,Macronutrient Intakes,Micronutrient Intakes,Nutrient Intakes,Nutritional Intakes
D005502 Food Substances taken in by the body to provide nourishment. Foods
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001241 Aspirin The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5) Acetylsalicylic Acid,2-(Acetyloxy)benzoic Acid,Acetysal,Acylpyrin,Aloxiprimum,Colfarit,Dispril,Easprin,Ecotrin,Endosprin,Magnecyl,Micristin,Polopirin,Polopiryna,Solprin,Solupsan,Zorprin,Acid, Acetylsalicylic
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D012459 Salicylates The salts or esters of salicylic acids, or salicylate esters of an organic acid. Some of these have analgesic, antipyretic, and anti-inflammatory activities by inhibiting prostaglandin synthesis. Salicylate,Salicylic Acids,Acids, Salicylic

Related Publications

P A Koch, and C A Schultz, and R J Wills, and S L Hallquist, and P G Welling
June 1978, Journal of pharmaceutical sciences,
P A Koch, and C A Schultz, and R J Wills, and S L Hallquist, and P G Welling
May 1963, Wiener klinische Wochenschrift,
P A Koch, and C A Schultz, and R J Wills, and S L Hallquist, and P G Welling
August 1976, Clinical pharmacology and therapeutics,
P A Koch, and C A Schultz, and R J Wills, and S L Hallquist, and P G Welling
November 1978, The Indian journal of medical research,
P A Koch, and C A Schultz, and R J Wills, and S L Hallquist, and P G Welling
January 1982, Journal of pharmaceutical sciences,
P A Koch, and C A Schultz, and R J Wills, and S L Hallquist, and P G Welling
April 1975, Clinical pharmacology and therapeutics,
P A Koch, and C A Schultz, and R J Wills, and S L Hallquist, and P G Welling
November 1984, Journal of pharmaceutical sciences,
P A Koch, and C A Schultz, and R J Wills, and S L Hallquist, and P G Welling
February 1983, The Journal of rheumatology,
P A Koch, and C A Schultz, and R J Wills, and S L Hallquist, and P G Welling
January 1978, Clinical pharmacokinetics,
P A Koch, and C A Schultz, and R J Wills, and S L Hallquist, and P G Welling
November 1986, Clinical pharmacology and therapeutics,
Copied contents to your clipboard!